Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

    ... intravascular hemolysis . Eculizumab , a monoclonal antibody against the complement protein C5, stops the intravascular ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.

    ... patients with daclizumab , a humanized monoclonal antibody to the interleukin-2 receptor; we now report our long-term ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. How I treat paroxysmal nocturnal hemoglobinuria.

    ... only curative therapy for PNH. Eculizumab , a monoclonal antibody that blocks terminal complement activation, is highly effective ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH).

    ... and for helping to decide when to initiate therapy with monoclonal antibody targeting the terminal complement protein C5 ( Eculizumab ), ...

    Research Article last updated 10/22/2013 - 3:44pm.

  5. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.

    ... such as thrombosis. Eculizumab , a humanized monoclonal antibody against the C5 complement protein, is the only effective drug ...

    Research Article last updated 05/14/2013 - 3:28pm.

  6. Paroxysmal nocturnal hemoglobinuria from bench to bedside

    ... reagent diagnosing PNH. Eculizumab , a humanized monoclonal antibody against C5, is the first effective drug therapy for PNH. ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. A Rare Genetic Polymorphism in C5 Confers Poor Response to the Anti-C5 Monoclonal Antibody Eculizumab by Nine Japanese Patients with PNH

    ...

    Research Review last updated 05/02/2016 - 9:25am.

  8. A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

    ... Phase 1 study of Atezolizumab (MPDL3280A, Anti-PD-L1 antibody) monoclonal antibody [mAb] in intermediate/high/very ...

    Clinical Trial last updated 04/27/2016 - 9:57am.

  9. Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab.

    ... labor and fetal loss. Eculizumab , a humanized monoclonal antibody directed against the terminal complement protein C5, has ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Robert A. Brodsky, MD

    ... from the loss of cell surface complement regulators. The monoclonal antibody eculizimab was developed to combat the thrombosis that ...

    Bio last updated 09/12/2016 - 11:04am.